Amgen (AMGN) Operating Expenses (2009 - 2026)

Amgen (AMGN) has reported Operating Expenses for 18 consecutive years, with $6.0 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses fell 14.62% year-over-year to $6.0 billion; the TTM figure through Mar 2026 stood at $26.7 billion (changed 0.11% YoY), while the FY2025 annual figure was $27.7 billion, up 5.75% from the prior year.
• Operating Expenses came in at $6.0 billion for Q1 2026 at Amgen, down from $7.1 billion in the prior quarter.
• The five-year high for Operating Expenses was $7.1 billion in Q4 2025, with the low at $3.7 billion in Q1 2022.
• Average Operating Expenses over 5 years is $5.7 billion, with a median of $6.5 billion recorded in 2024.
• Across the five-year window, Operating Expenses dropped 22.46% in 2022 and soared 54.3% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $4.6 billion in 2022, then jumped by 50.25% to $6.9 billion in 2023, then fell by 2.17% to $6.8 billion in 2024, then gained by 5.48% to $7.1 billion in 2025, then slipped by 16.71% to $6.0 billion in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $6.0 billion, $7.1 billion, and $7.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.